Therapeutic value of thioproperazine and the importance of the associated neurological disturbances

Clinical trials of thioproperazine (7843 R.P.; “Majeptil”) 2-dimethyl-sulphamoyl-10-(3-4′-methy1-1′-piperazinylpropyl) phenothiazine methanesulphonate, carried out in France by Delay, Deniker et al. (1959b); Perrin, Lambert et al. (1958); Coirault et al. (1959); and in America by Denber et al. (1959, 1960), have shown that it is a highly effective agent in the treatment of schizophrenia and acute mania. To examine the claims made for the drug's value in deteriorated or vegetative schizophrenics, and in other cases that have resisted chemotherapy, a trial was undertaken in this country.

Clinical trial of "stelazine" on apathetic chronic schizophrenics

“Stelazine” is the trademark name for Trifluoperazine. It is a derivative of phenothiazine with the following chemical formula: 10-3-(1-methyl-4-piperazinyl)-propyl-2-trifluoromethylphenothiazine dihydrochloride, or structurally:

The treatment of depressive states with imipramine hydrochloride (tofranil)

Drug treatment of depressive states has hitherto been somewhat disappointing but recent reports by Kuhn (1957, 1958), Kielholz and Battegay (1958) from Switzerland, and Azimo and Vispo (1958) from Canada have claimed that imipramine hydrochloride (Tofranil) has “thymoleptic” qualities and is of specific therapeutic value in states of endogenous depression and allied affective disorders.